Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Depreciation & Amortization (CF) (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $451000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 1.35% year-over-year to $451000.0; the TTM value through Sep 2025 reached $1.8 million, up 2.43%, while the annual FY2024 figure was $1.7 million, 14.36% up from the prior year.
  • Depreciation & Amortization (CF) reached $451000.0 in Q3 2025 per NWBO's latest filing, roughly flat from $451000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $524000.0 in Q2 2022 and bottomed at $68000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $325315.8, with a median of $416000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 3750.0% in 2021, then crashed 33.21% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $84000.0 in 2021, then soared by 278.57% to $318000.0 in 2022, then surged by 33.33% to $424000.0 in 2023, then rose by 3.07% to $437000.0 in 2024, then grew by 3.2% to $451000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $451000.0 in Q3 2025, $451000.0 in Q2 2025, and $434000.0 in Q1 2025.